Invention Grant
US08722705B2 Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents 有权
用3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基) - 哌啶-2,6-二酮与第二活性剂组合治疗弥漫性大B细胞淋巴瘤的方法

  • Patent Title: Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
  • Patent Title (中): 用3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基) - 哌啶-2,6-二酮与第二活性剂组合治疗弥漫性大B细胞淋巴瘤的方法
  • Application No.: US13942232
    Application Date: 2013-07-15
  • Publication No.: US08722705B2
    Publication Date: 2014-05-13
  • Inventor: Jerome B. Zeldis
  • Applicant: Celgene Corporation
  • Applicant Address: US NJ Summit
  • Assignee: Celgene Corporation
  • Current Assignee: Celgene Corporation
  • Current Assignee Address: US NJ Summit
  • Agency: Jones Day
  • Main IPC: A61K31/445
  • IPC: A61K31/445
Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Information query
Patent Agency Ranking
0/0